SCMP: Yicura BioMed Eyes Hong Kong IPO, CEO Calls for More Patient Capital
According to the South China Morning Post, Xian Jin, CEO of Hong Kong Science Park-based biotech startup Yicura BioMed, stated that the company plans to pursue an initial public offering (IPO) in Hong Kong as soon as feasible. He noted that Hong Kong's biotech ecosystem requires more "patient capital" as well as talent capable of commercializing research and development outcomes.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
Samsung Electronics rose 4.05% from its previous close and is currently trading at ₩198,000.
-
2
SK Hynix rose 5.01% from its previous close, currently trading at ₩1,153,000.
-
3
NEAR (NEAR Protocol) surged 6.1% in 4 hours, currently trading at $3.358
-
4
SK Hynix rose 6.56% from its previous close, currently trading at ₩1,170,000.
-
5
US airlines, Microsoft, banks, the NSA, and Apple have suffered consecutive outages, with varying causes and recovery progress
-
6
CNBC: Japan's October Exports Up 20.5% YoY, Semiconductor Equipment Shipments Surge 49.7%
-
7
SCMP: Hang Lung Properties Completes HK$998M Land Premium for 37 Shouson Hill Road Project
-
8
UBS expects the renminbi to strengthen to 6.25 per US dollar by the end of 2027.
-
9
CryptoSlate: PEAR Team Reports Simulated Post-Training Model Succeeds 18 Out of 30 Times in Embodied Robotics Tests
-
10
JPMorgan Chase: ConvaTec Group’s earnings update is expected to dispel market concerns over achieving its 2026 guidance
Markets Today
Recommended Reading


